Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPLZL.L Regulatory News (PLZL)

  • There is currently no data for PLZL

Rule 8.1- OJSC Polyus Gold

17 Jul 2009 09:55

RNS Number : 8562V
Renaissance Capital Limited
17 July 2009
Β 

ο»Ώ

Β  FORM 8.1

DEALINGS BY OFFERORS, OFFEREE COMPANIES OR THEIR ASSOCIATES

FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

(RulesΒ 8.1(a) and (b)(i)Β ofΒ theΒ TakeoverΒ Code)

1. KEY INFORMATION

Name of person dealingΒ (Note 1)

Subsidiaries of Renaissance Capital Holdings Limited trading under theΒ Renaissance CapitalΒ brand

Company dealt in

OJSC Polyus Gold

Class of relevant security to which the dealings being disclosed relateΒ (NoteΒ 2)

1 RUB ordinary (OJSC Polyus Gold)

Date of dealing

16Β JulyΒ 2009

2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE

(a) InterestsΒ and short positionsΒ (following dealing) in the class of relevant security dealt inΒ (Note 3)

Long

Short

Number (%)

Number (%)

(1) Relevant securitiesΒ 

246,379 (0.12%)

224,406 (0.12%)

(2) Derivatives (other than options)

1,240,000 (0.65%)

(3) Options and agreements to purchase/sell

Total

Β 246,379 (0.12%)

1,494,406 (0.78%)

(b) InterestsΒ and short positionsΒ in relevant securities of the company, other than theΒ classΒ dealt inΒ (Note 3)

Class of relevant security:

Long

Short

Number (%)

Number (%)

(1) Relevant securitiesΒ 

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

(c) Rights to subscribeΒ (Note 3)

Class of relevant security:

Details

3. DEALINGSΒ (Note 4)

(a) Purchases and sales

Total number of securities purchased

Highest price paidΒ (Note 3)

Lowest price paidΒ (Note 3)

1,511Β ordinary shares

17,000Β ordinary shares

14,600Β ADRs (conversion ratio 1 ADR:0.5 share)

USDΒ 36.544

RURΒ 1174.893

USDΒ 19.900

USDΒ 35.461

RURΒ 886.872

USDΒ 19.701

Total number of securities sold

Highest price receivedΒ (Note 3)

Lowest price receivedΒ (Note 3)

500Β ordinary shares

18,332Β ordinary shares

14,600Β ADRs (conversion ratio 1 ADR:0.5 share)

USDΒ 36.662

RURΒ 1171.125

USDΒ 19.896

USDΒ 36.358

RURΒ 886.872

USDΒ 19.726

(b) Derivatives transactions (other than options)

Product name,Β 

e.g. CFD

Long/shortΒ (Note 6)

Number of securitiesΒ (Note 7)

Price per unitΒ (Note 5)

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Product name,

e.g.Β callΒ option

Writing, selling, purchasing, varying etc.

Number of securitiesΒ to which the option relatesΒ (Note 7)

Exercise

priceΒ 

Type,Β e.g. American, European etc.

ExpiryΒ 

date

Option money

paid/receivedΒ per unitΒ (Note 5)

(ii) Exercising

Product name,Β e.g.Β call option

Number of securitiesΒ 

Exercise priceΒ per unitΒ (Note 5)

(d) Other dealings (including new securities)Β (Note 4)

Nature of transactionΒ (Note 8)

Details

PriceΒ per unitΒ (if applicable)Β (Note 5)Β 

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relatingΒ toΒ the voting rights of any relevant securities under any option referred to on this form orΒ relating to the voting rights orΒ future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached?Β (Note 9) YES

Date of disclosure

17Β JulyΒ 2009

Contact name

Bridget Andrews

Telephone number

020 7367 7988

Name of offeree/offerorΒ with whichΒ associated

Jenington International Inc (an indirect wholly owned subsidiary of OJSC Polyus Gold)Β 

Specify category and nature of associate statusΒ (Note 10)

Acting in concertΒ as a result of a 50%Β less one-half of one shareΒ ownership of Renaissance Financial Holdings Limited by ONEXIM Group.

Notes

TheΒ NotesΒ onΒ Form 8.1 can be viewed on the Takeover Panel's website atΒ www.thetakeoverpanel.org.uk

SUPPLEMENTAL FORM 8

DETAILS OF OPENΒ POSITIONSΒ 

(This form should be attached to Form 8.1, Form 8.1(b)(ii)Β or Form 8.3, as appropriate)

OPENΒ POSITIONSΒ (NoteΒ 1)

Product name,

e.g.Β call option

Written or purchased

Number of securitiesΒ to which the option or derivative relates

Exercise priceΒ (Note 2)

Type, e.g. American, European etc.

Expiry date

Β Total return swap

Written

1,750,000 ADRs

Market price at termination date

Traders agreed on securities settlement - confirmation stated cash settled

24 November 2009

Total return swap

Written

730,000 ADRs

Market price at termination date

Traders agreed on securities settlement - confirmation stated cash settled

17 July 2009

Notes

1.Β Where there are open option positions or open derivative positions (except for CFDs), full details should be given.Β Β Full details of anyΒ Β existing agreements to purchase or to sellΒ Β shouldΒ also be given on this form.Β Β 

2. For all prices and other monetary amounts, the currency must be stated.

For details of the Code's dealing disclosure requirements, see Rule 8 and its Notes which can be viewed on the Takeover Panel's website atΒ www.thetakeoverpanel.org.uk

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
DCCVDLBFKDBEBBL
Date   Source Headline
23rd Sep 20202:53 pmRNSPolyus to consolidate 100% of SL Gold
22nd Sep 20202:35 pmRNSResults of exercise of pre-emptive right
22nd Sep 202012:33 pmRNSConsolidation of Lenzoloto assets
7th Sep 20207:53 amRNS1H 2020 Dividend Recommendation
7th Sep 20207:29 amRNSNotice of EGM - replacement
7th Sep 20207:00 amRNSFinancial results for the second quarter of 2020
1st Sep 20209:06 amRNSNotice of financial results 2Q2020
20th Aug 202011:20 amRNSNotice of EGM - Replacement
20th Aug 20209:19 amRNSNotice of EGM
20th Aug 20209:12 amRNSAppointment of Senior Independent Director
19th Aug 20201:44 pmRNSResult of AGM
17th Aug 20207:29 amRNSConsolidation of Lenzoloto assets
7th Aug 202010:54 amRNSThe commencement date of placement of the shares
7th Aug 20207:00 amRNSPre-emption right notice
6th Aug 20205:52 pmRNSDetermination of the issuance price
30th Jul 20205:48 pmRNSDirector/PDMR Shareholding
16th Jul 20207:00 amRNSTrading update for the second quarter of 2020
15th Jul 20203:52 pmRNS2H 2019 Dividend Recommendation and 2019 AGM
23rd Jun 20203:08 pmRNSEGM results
1st Jun 20207:00 amRNSFinancial results for the first quarter of 2020
28th May 20209:10 amRNSDirector/PDMR Shareholding
22nd May 20202:20 pmRNSNotice of financial results for 1Q2020
18th May 20204:05 pmRNSThe proposed placement of new ordinary shares
18th May 20203:44 pmRNSNotice of EGM
14th May 20203:07 pmRNSCompletion of the early redemption
14th May 20202:57 pmRNSCompletion of the early redemption
11th May 202012:01 pmRNSDirector/PDMR Shareholding
30th Apr 20206:30 pmRNSPolyus publishes its 2019 Annual Review
30th Apr 20201:15 pmRNSDirector/PDMR Shareholding
29th Apr 20204:14 pmRNSOre Reserves and Mineral Resources Update
29th Apr 20203:46 pmRNSDirector/PDMR Shareholding
23rd Apr 20207:00 amRNSTrading update for the first quarter of 2020
17th Apr 20205:29 pmRNSDirector/PDMR Shareholding
17th Apr 20205:02 pmRNSOptional redemption of 2021 convertible bonds
17th Apr 20204:45 pmRNSNotice to Bondholders: Optional Redemption Notice
30th Mar 20205:36 pmRNSCompany update on COVID-19 prevention procedures
26th Mar 20205:17 pmRNSDirector/PDMR Shareholding
26th Mar 20203:07 pmRNSEstablishment of a COVID-19 Fund
19th Feb 20204:38 pmRNSPolyus' MSCI ESG rating upgraded to A
11th Feb 20207:00 amRNSFinancial results for 4Q and FY2019
4th Feb 20207:00 amRNSNotice of financial results for 4Q and FY2019
28th Jan 20207:00 amRNSTrading update for 4Q and FY2019
24th Jan 20207:00 amRNSS&P Global Ratings revises Outlook on PJSC Polyus
31st Dec 20197:46 amRNSDirector/PDMR Shareholding
27th Dec 201911:23 amRNSResults of the share issuance
27th Dec 201911:12 amRNSResults of the closed subscription for shares
24th Dec 20191:01 pmRNSResults of exercise of pre-emption right
24th Dec 201911:08 amRNSDirector/PDMR Shareholding
6th Nov 20195:51 pmRNSNew shares issuance update
6th Nov 20194:24 pmRNSNotice of pre-emption right

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.